Filing Flows › UroGen Pharma (URGN) › Q2 2025
UroGen Pharma (URGN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
UroGen Pharma (URGN) reported revenue of $24.2M for the second quarter 2025 (Q2 2025), +11% from a year earlier and +20% from the quarter before. Operating margin was -171.2%, net loss $49.9M (206.2% of revenue).
UroGen Pharma, Q2 2025: revenue $24.2M (+11% year over year), operating margin -171.2%, net loss $49.9M, operating cash flow −$39.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.2M | +20% | +11% |
| Operating profit | −$41.4M | — | — |
| Net earnings | −$49.9M | — | — |
| Operating cash flow | −$39.8M | — | — |
What changed
Revenue was $24.2M in Q2 2025, up 11% year over year and up 20% from the previous quarter.
Gross margin was 85.3%, down 4.5 points from a year earlier. Operating costs exceeded revenue by $41.4M, an operating margin of -171.2%. Operating expenses grew 37% against revenue growth of 11%. The fastest-growing cost line was SG&A (+44%). The quarter ended with a net loss of $49.9M, wider than the previous quarter's $43.8M loss.
Operating cash flow was −$39.8M. Non-cash charges added back $100K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items added $7.3M. Capital expenditures of $141K exceeded it, leaving free cash flow of −$40.0M.
Questions
What was UroGen Pharma's revenue in the second quarter 2025?
UroGen Pharma (URGN) reported revenue of $24.2M for the second quarter 2025 (Q2 2025), +11% from a year earlier and +20% from the quarter before.
Was UroGen Pharma profitable in the second quarter 2025?
Operating loss was $41.4M (-171.2% of revenue) and net loss $49.9M.
Source: UroGen Pharma 10-Q on SEC EDGAR.